FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205535523> ?p ?o ?g. }

• W4205535523 endingPage "e003518" @default.
• W4205535523 startingPage "e003518" @default.
• W4205535523 abstract "Matrix metalloproteinase 9 (MMP9) is implicated in protumorigenic processes. Targeting either stromal or epithelial MMP9 reduces the incidence of metastasis. Andecaliximab is a monoclonal antibody that targets MMP9 with high affinity and selectivity. However, no study has examined whether the inhibition of T-cell programmed death 1 (PD-1) in the presence of andecaliximab increases activated lymphocyte infiltration into the tumor, thereby increasing antitumor activity more than that in anti-PD-1 monotherapy. In this study, we assessed the safety, pharmacokinetics (PK), exploratory biomarkers, and preliminary efficacy of andecaliximab as monotherapy and in combination with nivolumab in Japanese patients with advanced or recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma.This phase 1b study comprised four cohorts enrolling Japanese patients with gastric or GEJ adenocarcinoma. This paper concerns cohorts 1 and 4; cohorts 2 and 3 will be reported subsequently. Cohort 1 enrolled patients with human epidermal growth factor receptor 2 (HER2)-negative tumors (n=8) who received andecaliximab monotherapy (800 mg by intravenous infusion every 2 weeks (Q2W)), and cohort 4 enrolled patients irrespective of their HER2 status (n=10) who received 800 mg of andecaliximab in combination with nivolumab Q2W. Safety, dose-limiting toxicities (DLTs), PK, pharmacodynamics, and biomarkers were assessed in both cohorts.PK of andecaliximab in Japanese patients with gastric or GEJ adenocarcinoma was similar to that reported in non-Japanese patients with advanced solid tumors. Andecaliximab monotherapy and in combination with nivolumab demonstrated no DLTs in cohort 1 and 4, respectively. Toxicities were manageable and well tolerated in both cohorts. The median progression-free survival was 1.4 months (90% CI, 0.5 to 5.4) and 4.6 months (90% CI, 0.9 to not reached) in cohorts 1 and 4, respectively. The objective response rate was 50% (90% CI, 22% to 78%) in cohort 4, and in some patients, the combination therapy was effective regardless of the biomarker status.The andecaliximab-nivolumab combination demonstrated a manageable safety profile and promising clinical activity in patients with advanced gastric adenocarcinoma.NCT02862535." @default.
• W4205535523 created "2022-01-25" @default.
• W4205535523 creator A5002562596 @default.
• W4205535523 creator A5002809808 @default.
• W4205535523 creator A5010090426 @default.
• W4205535523 creator A5014800720 @default.
• W4205535523 creator A5015229603 @default.
• W4205535523 creator A5022845423 @default.
• W4205535523 creator A5023430800 @default.
• W4205535523 creator A5040676201 @default.
• W4205535523 creator A5044392059 @default.
• W4205535523 creator A5051327921 @default.
• W4205535523 creator A5051600962 @default.
• W4205535523 creator A5052643803 @default.
• W4205535523 creator A5058524907 @default.
• W4205535523 creator A5073330859 @default.
• W4205535523 creator A5083889178 @default.
• W4205535523 creator A5089345348 @default.
• W4205535523 date "2022-01-01" @default.
• W4205535523 modified "2023-09-26" @default.
• W4205535523 title "Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study" @default.
• W4205535523 cites W1428077152 @default.
• W4205535523 cites W16797474 @default.
• W4205535523 cites W1978833060 @default.
• W4205535523 cites W1988556605 @default.
• W4205535523 cites W2016859011 @default.
• W4205535523 cites W2020947105 @default.
• W4205535523 cites W2042699075 @default.
• W4205535523 cites W2116305904 @default.
• W4205535523 cites W2127761846 @default.
• W4205535523 cites W2154401382 @default.
• W4205535523 cites W2167930666 @default.
• W4205535523 cites W2335839753 @default.
• W4205535523 cites W2740445104 @default.
• W4205535523 cites W2763064222 @default.
• W4205535523 cites W2801869430 @default.
• W4205535523 cites W2903322254 @default.
• W4205535523 cites W2925632200 @default.
• W4205535523 cites W3049895374 @default.
• W4205535523 cites W3127702912 @default.
• W4205535523 cites W948010275 @default.
• W4205535523 doi "https://doi.org/10.1136/jitc-2021-003518" @default.
• W4205535523 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34992093" @default.
• W4205535523 hasPublicationYear "2022" @default.
• W4205535523 type Work @default.
• W4205535523 citedByCount "3" @default.
• W4205535523 countsByYear W42055355232022 @default.
• W4205535523 countsByYear W42055355232023 @default.
• W4205535523 crossrefType "journal-article" @default.
• W4205535523 hasAuthorship W4205535523A5002562596 @default.
• W4205535523 hasAuthorship W4205535523A5002809808 @default.
• W4205535523 hasAuthorship W4205535523A5010090426 @default.
• W4205535523 hasAuthorship W4205535523A5014800720 @default.
• W4205535523 hasAuthorship W4205535523A5015229603 @default.
• W4205535523 hasAuthorship W4205535523A5022845423 @default.
• W4205535523 hasAuthorship W4205535523A5023430800 @default.
• W4205535523 hasAuthorship W4205535523A5040676201 @default.
• W4205535523 hasAuthorship W4205535523A5044392059 @default.
• W4205535523 hasAuthorship W4205535523A5051327921 @default.
• W4205535523 hasAuthorship W4205535523A5051600962 @default.
• W4205535523 hasAuthorship W4205535523A5052643803 @default.
• W4205535523 hasAuthorship W4205535523A5058524907 @default.
• W4205535523 hasAuthorship W4205535523A5073330859 @default.
• W4205535523 hasAuthorship W4205535523A5083889178 @default.
• W4205535523 hasAuthorship W4205535523A5089345348 @default.
• W4205535523 hasBestOaLocation W42055355231 @default.
• W4205535523 hasConcept C111113717 @default.
• W4205535523 hasConcept C112705442 @default.
• W4205535523 hasConcept C121608353 @default.
• W4205535523 hasConcept C126322002 @default.
• W4205535523 hasConcept C143998085 @default.
• W4205535523 hasConcept C197934379 @default.
• W4205535523 hasConcept C2777701055 @default.
• W4205535523 hasConcept C2778375690 @default.
• W4205535523 hasConcept C2780030458 @default.
• W4205535523 hasConcept C71924100 @default.
• W4205535523 hasConcept C72563966 @default.
• W4205535523 hasConcept C90924648 @default.
• W4205535523 hasConceptScore W4205535523C111113717 @default.
• W4205535523 hasConceptScore W4205535523C112705442 @default.
• W4205535523 hasConceptScore W4205535523C121608353 @default.
• W4205535523 hasConceptScore W4205535523C126322002 @default.
• W4205535523 hasConceptScore W4205535523C143998085 @default.
• W4205535523 hasConceptScore W4205535523C197934379 @default.
• W4205535523 hasConceptScore W4205535523C2777701055 @default.
• W4205535523 hasConceptScore W4205535523C2778375690 @default.
• W4205535523 hasConceptScore W4205535523C2780030458 @default.
• W4205535523 hasConceptScore W4205535523C71924100 @default.
• W4205535523 hasConceptScore W4205535523C72563966 @default.
• W4205535523 hasConceptScore W4205535523C90924648 @default.
• W4205535523 hasIssue "1" @default.
• W4205535523 hasLocation W42055355231 @default.
• W4205535523 hasLocation W42055355232 @default.
• W4205535523 hasLocation W42055355233 @default.
• W4205535523 hasLocation W42055355234 @default.
• W4205535523 hasOpenAccess W4205535523 @default.
• W4205535523 hasPrimaryLocation W42055355231 @default.
• W4205535523 hasRelatedWork W1582278270 @default.

• next